The highlight of the company’s presence in Madrid is the presentation of registrational Phase 3 results for Arcotatug Tavetecan (IBI343/TAK-921) in patients with advanced gastric or gastroesophageal junction adenocarcinoma. This study, known as G-HOPE-001, has been selected as a Late-Breaking Abstract and is slated for an oral session on October 23, with Dr. Kohei Shitara serving as the lead presenter.
Innovent Biologics to Unveil New Oncology Pipeline Data at 2026 ESMO
Innovent Biologics is set to showcase a broad portfolio of next-generation cancer therapies at the 2026 European Society for Medical Oncology Annual Meeting in Madrid. The presentation, scheduled for October 23–27, will feature registrational data for the company's CLDN18.2 antibody-drug conjugate, Arcotatug Tavetecan, alongside new clinical insights into its bispecific and HER2-targeting programs.
Beyond this registrational trial, Innovent will provide updates on its immuno-oncology and ADC pipeline. Key disclosures include first-in-class multi-regional Phase 1 data for IBI3001, an EGFR/B7H3 bispecific ADC, and Phase 2 efficacy results for the HER2-targeting IBI354 in first-line breast cancer. Dr. Hui Zhou, Innovent’s Chief R&D Officer for Oncology, noted that the data will further validate the potential of these molecules as next-generation treatment options. The company will also present several updates regarding its TYVYT (sintilimab) program, spanning research into lung, nasopharyngeal, and colorectal cancers, reflecting its ongoing commitment to expanding clinical applications for its core oncology assets.
Comments (0)
No comments yet. Be the first!